Recall D-0290-2026

US Class II Ongoing · initiated 2026-01-02

Recalling firm

Cipla USA, Inc., NJ

Product

Lanreotide Injection, 120 mg/0.5 mL, 0.5 mL per pre-filled syringe, For deep subcutaneous injection, Rx Only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC: 69097-870-67

Reason for recall

Presence of Particulate Matter.

← All recalls